Sandy Spring Bank increased its position in Johnson & Johnson (NYSE:JNJ) by 2.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 143,215 shares of the company’s stock after acquiring an additional 3,702 shares during the period. Johnson & Johnson makes up 1.5% of Sandy Spring Bank’s portfolio, making the stock its 11th biggest position. Sandy Spring Bank’s holdings in Johnson & Johnson were worth $21,322,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Winslow Evans & Crocker Inc. boosted its position in shares of Johnson & Johnson by 0.3% during the 2nd quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock valued at $3,037,000 after purchasing an additional 69 shares in the last quarter. Lathrop Investment Management Corp raised its position in Johnson & Johnson by 1.4% during the second quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock valued at $689,000 after acquiring an additional 69 shares in the last quarter. Reik & CO. LLC raised its position in Johnson & Johnson by 0.4% during the second quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock valued at $2,493,000 after acquiring an additional 70 shares in the last quarter. Delta Investment Management LLC grew its holdings in Johnson & Johnson by 1.0% during the second quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock valued at $1,041,000 after purchasing an additional 71 shares during the last quarter. Finally, IFG Advisory LLC grew its holdings in Johnson & Johnson by 0.4% during the second quarter. IFG Advisory LLC now owns 16,170 shares of the company’s stock valued at $2,274,000 after purchasing an additional 71 shares during the last quarter. Hedge funds and other institutional investors own 67.44% of the company’s stock.
JNJ has been the topic of several analyst reports. Credit Suisse Group increased their price target on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday, October 14th. Raymond James reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Friday. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Cantor Fitzgerald lifted their price target on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, October 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $164.93.
In related news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.27% of the company’s stock.
NYSE:JNJ opened at $146.36 on Friday. The stock’s 50-day simple moving average is $145.51 and its 200 day simple moving average is $146.57. The firm has a market capitalization of $385.30 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The company had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. During the same period last year, the company earned $2.12 earnings per share. The firm’s revenue was up 1.7% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post 7.99 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a dividend of $1.01 per share. The ex-dividend date is Monday, November 23rd. This represents a $4.04 annualized dividend and a yield of 2.76%. Johnson & Johnson’s dividend payout ratio is currently 46.54%.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also: Trading signals using Bollinger bands
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.